FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2607200433> ?p ?o ?g. }

• W2607200433 endingPage "1332" @default.
• W2607200433 startingPage "1325" @default.
• W2607200433 abstract "BackgroundRAS assessment is mandatory for therapy decision in metastatic colorectal cancer (mCRC) patients. This determination is based on tumor tissue, however, genotyping of circulating tumor (ct)DNA offers clear advantages as a minimally invasive method that represents tumor heterogeneity. Our study aims to evaluate the use of ctDNA as an alternative for determining baseline RAS status and subsequent monitoring of RAS mutations during therapy as a component of routine clinical practice.Patients and methodsRAS mutational status in plasma was evaluated in mCRC patients by OncoBEAM™ RAS CRC assay. Concordance of results in plasma and tissue was retrospectively evaluated.RAS mutations were also prospectively monitored in longitudinal plasma samples from selected patients.ResultsAnalysis of RAS in tissue and plasma samples from 115 mCRC patients showed a 93% overall agreement. Plasma/tissue RAS discrepancies were mainly explained by spatial and temporal tumor heterogeneity. Analysis of clinico-pathological features showed that the site of metastasis (i.e. peritoneal, lung), the histology of the tumor (i.e. mucinous) and administration of treatment previous to blood collection negatively impacted the detection of RAS in ctDNA. In patients with baseline mutant RAS tumors treated with chemotherapy/antiangiogenic, longitudinal analysis of RAS ctDNA mirrored response to treatment, being an early predictor of response. In patients RAS wt, longitudinal monitoring of RAS ctDNA revealed that OncoBEAM was useful to detect emergence of RAS mutations during anti-EGFR treatment.ConclusionThe high overall agreement in RAS mutational assessment between plasma and tissue supports blood-based testing with OncoBEAM™ as a viable alternative for genotyping RAS of mCRC patients in routine clinical practice. Our study describes practical clinico-pathological specifications to optimize RAS ctDNA determination. Moreover, OncoBEAM™ is useful to monitor RAS in patients undergoing systemic therapy to detect resistance and evaluate the efficacy of particular treatments." @default.
• W2607200433 created "2017-04-28" @default.
• W2607200433 creator A5001410842 @default.
• W2607200433 creator A5008993020 @default.
• W2607200433 creator A5016992044 @default.
• W2607200433 creator A5018699719 @default.
• W2607200433 creator A5029048001 @default.
• W2607200433 creator A5043472954 @default.
• W2607200433 creator A5046102762 @default.
• W2607200433 creator A5047299361 @default.
• W2607200433 creator A5049272086 @default.
• W2607200433 creator A5049351801 @default.
• W2607200433 creator A5050923145 @default.
• W2607200433 creator A5051681898 @default.
• W2607200433 creator A5051736148 @default.
• W2607200433 creator A5051842643 @default.
• W2607200433 creator A5056088022 @default.
• W2607200433 creator A5064267997 @default.
• W2607200433 creator A5066667956 @default.
• W2607200433 creator A5071636624 @default.
• W2607200433 creator A5083616708 @default.
• W2607200433 creator A5084392897 @default.
• W2607200433 creator A5090367371 @default.
• W2607200433 date "2017-06-01" @default.
• W2607200433 modified "2023-10-18" @default.
• W2607200433 title "Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients" @default.
• W2607200433 cites W1904761682 @default.
• W2607200433 cites W1914351667 @default.
• W2607200433 cites W2006168411 @default.
• W2607200433 cites W2027371008 @default.
• W2607200433 cites W2062109911 @default.
• W2607200433 cites W2112761899 @default.
• W2607200433 cites W2116731538 @default.
• W2607200433 cites W2141630197 @default.
• W2607200433 cites W2154018281 @default.
• W2607200433 cites W2171237493 @default.
• W2607200433 cites W2314682804 @default.
• W2607200433 cites W2470575266 @default.
• W2607200433 cites W2553710623 @default.
• W2607200433 cites W2560160922 @default.
• W2607200433 cites W4235642752 @default.
• W2607200433 doi "https://doi.org/10.1093/annonc/mdx125" @default.
• W2607200433 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5834035" @default.
• W2607200433 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28419195" @default.
• W2607200433 hasPublicationYear "2017" @default.
• W2607200433 type Work @default.
• W2607200433 sameAs 2607200433 @default.
• W2607200433 citedByCount "254" @default.
• W2607200433 countsByYear W26072004332017 @default.
• W2607200433 countsByYear W26072004332018 @default.
• W2607200433 countsByYear W26072004332019 @default.
• W2607200433 countsByYear W26072004332020 @default.
• W2607200433 countsByYear W26072004332021 @default.
• W2607200433 countsByYear W26072004332022 @default.
• W2607200433 countsByYear W26072004332023 @default.
• W2607200433 crossrefType "journal-article" @default.
• W2607200433 hasAuthorship W2607200433A5001410842 @default.
• W2607200433 hasAuthorship W2607200433A5008993020 @default.
• W2607200433 hasAuthorship W2607200433A5016992044 @default.
• W2607200433 hasAuthorship W2607200433A5018699719 @default.
• W2607200433 hasAuthorship W2607200433A5029048001 @default.
• W2607200433 hasAuthorship W2607200433A5043472954 @default.
• W2607200433 hasAuthorship W2607200433A5046102762 @default.
• W2607200433 hasAuthorship W2607200433A5047299361 @default.
• W2607200433 hasAuthorship W2607200433A5049272086 @default.
• W2607200433 hasAuthorship W2607200433A5049351801 @default.
• W2607200433 hasAuthorship W2607200433A5050923145 @default.
• W2607200433 hasAuthorship W2607200433A5051681898 @default.
• W2607200433 hasAuthorship W2607200433A5051736148 @default.
• W2607200433 hasAuthorship W2607200433A5051842643 @default.
• W2607200433 hasAuthorship W2607200433A5056088022 @default.
• W2607200433 hasAuthorship W2607200433A5064267997 @default.
• W2607200433 hasAuthorship W2607200433A5066667956 @default.
• W2607200433 hasAuthorship W2607200433A5071636624 @default.
• W2607200433 hasAuthorship W2607200433A5083616708 @default.
• W2607200433 hasAuthorship W2607200433A5084392897 @default.
• W2607200433 hasAuthorship W2607200433A5090367371 @default.
• W2607200433 hasBestOaLocation W26072004331 @default.
• W2607200433 hasConcept C104317684 @default.
• W2607200433 hasConcept C121608353 @default.
• W2607200433 hasConcept C126322002 @default.
• W2607200433 hasConcept C135763542 @default.
• W2607200433 hasConcept C142724271 @default.
• W2607200433 hasConcept C143998085 @default.
• W2607200433 hasConcept C160798450 @default.
• W2607200433 hasConcept C185592680 @default.
• W2607200433 hasConcept C2778332735 @default.
• W2607200433 hasConcept C2779013556 @default.
• W2607200433 hasConcept C2781187634 @default.
• W2607200433 hasConcept C31467283 @default.
• W2607200433 hasConcept C526805850 @default.
• W2607200433 hasConcept C55493867 @default.
• W2607200433 hasConcept C71924100 @default.
• W2607200433 hasConceptScore W2607200433C104317684 @default.
• W2607200433 hasConceptScore W2607200433C121608353 @default.
• W2607200433 hasConceptScore W2607200433C126322002 @default.
• W2607200433 hasConceptScore W2607200433C135763542 @default.
• W2607200433 hasConceptScore W2607200433C142724271 @default.

• next